DETERMINE-preserved – Dapagliflozin effect on exercise capacity using a 6-minute walk test in patients with heart failure with preserved ejection fraction

Trial Identifier: D169EC00001
Sponsor: AstraZeneca
NCTID:: NCT03877224
Start Date: April 2019
Primary Completion Date: July 2020
Study Completion Date: July 2020

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Afrikaans Translation
Bulgarian Translation
Danish Translation
English UK Translation
French Canadian Translation
Italian Translation
Japanese Translation
Korean Translation
Portuguese Translation
Slovak Translation
Spanish Translation
Spanish US Translation
Swedish Translation

Trial Locations